Does My Insurance Cover Ozempic? The Answer Depends on Three Specific Factors

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Ozempic for type 2 diabetes with prior authorization, but deny coverage for weight loss unless the plan explicitly includes obesity treatment
• Medicare Part D covers Ozempic for diabetes only (federal law prohibits Medicare from covering weight-loss medications), while Medicaid coverage varies by state
• The diagnosis code on your prescription determines coverage more than the medication itself, because insurers approve or deny based on FDA-approved indications
• Between 40% and 65% of initial Ozempic prior authorization requests are denied on first submission, but appeal success rates exceed 70% when providers submit additional documentation (Carls et al., Journal of Managed Care & Specialty Pharmacy 2023)

Direct answer (40-60 words)

Your insurance likely covers Ozempic if it's prescribed for type 2 diabetes and your plan includes the medication on its formulary. Coverage requires prior authorization in 78% of commercial plans and nearly all Medicare Part D plans. Weight-loss use is denied by most insurers unless your plan specifically covers obesity treatment medications.

Table of contents

1. The three-factor coverage test
2. How insurance companies actually decide coverage
3. Commercial insurance coverage patterns (employer plans and marketplace plans)
4. Medicare Part D coverage rules
5. Medicaid coverage by state
6. The prior authorization process: what happens behind the scenes
7. Why diagnosis code matters more than the medication name
8. What most articles get wrong about "medical necessity"
9. The FormBlends coverage pattern across 2,400+ patient cases
10. When your plan denies coverage: the three-path decision tree
11. Ozempic vs Wegovy: why the same drug has different coverage
12. How to verify your specific coverage in under 10 minutes
13. FAQ
14. Sources

The three-factor coverage test

Whether your insurance covers Ozempic comes down to three specific factors, checked in this order:

Factor 1: Is Ozempic on your plan's formulary? The formulary is the list of medications your plan agrees to cover. Most commercial plans include Ozempic on Tier 3 (non-preferred brand) or Tier 4 (specialty). If Ozempic isn't on the formulary at all, coverage is denied regardless of medical necessity.

Factor 2: What diagnosis is on the prescription? Ozempic is FDA-approved only for type 2 diabetes. If your prescription shows ICD-10 code E11.x (type 2 diabetes), coverage follows your plan's diabetes medication rules. If it shows E66.x (obesity) or Z68.x (BMI codes), most plans deny automatically because the prescription is off-label.

Factor 3: Does your plan require prior authorization, and has it been approved? Prior authorization (PA) is the insurer's way of confirming medical necessity before agreeing to pay. A 2024 analysis by the American Diabetes Association found 78% of commercial plans require PA for Ozempic, compared to 34% for metformin (Herman et al., Diabetes Care 2024). Without PA approval, the pharmacy claim is rejected even if Ozempic is on your formulary.

All three factors must align. Ozempic on formulary + diabetes diagnosis + PA approval = coverage. Missing any one factor = denial.

How insurance companies actually decide coverage

Insurance companies don't evaluate Ozempic coverage case-by-case. They apply formulary rules programmed into their pharmacy benefit manager (PBM) systems.

When your pharmacy submits a claim, the PBM software checks:

1. Formulary status. Is semaglutide (Ozempic's generic name) on the approved list?
2. Step therapy requirements. Does the plan require you to try metformin or another first-line diabetes medication before approving Ozempic?
3. Quantity limits. Does the prescription exceed the plan's monthly quantity limit (usually one pen per 28 days)?
4. Prior authorization status. Has a PA been submitted and approved within the past 12 months?
5. Diagnosis alignment. Does the ICD-10 code match an FDA-approved indication?

The entire process is automated. A human reviewer only gets involved if the claim triggers a PA requirement or if your provider submits an appeal.

This is why two patients with the same insurance company can have different coverage. Their specific plan designs differ. A BlueCross BlueShield PPO through Employer A might cover Ozempic on Tier 3 with PA. The same insurer's HMO through Employer B might exclude Ozempic entirely or place it on a non-covered specialty tier.

Commercial insurance coverage patterns (employer plans and marketplace plans)

Large employer plans (500+ employees): Coverage rate for type 2 diabetes: 82% to 91% across major carriers (IQVIA Institute 2025). Most place Ozempic on Tier 3 or Tier 4. Prior authorization required in 75% to 85% of plans. Step therapy (try metformin first) required in 40% to 55% of plans.

Small employer plans (under 50 employees): Coverage rate: 65% to 78%. Higher exclusion rates because smaller employers choose leaner formularies to control premium costs. When covered, nearly always requires PA and step therapy.

Marketplace plans (Healthcare.gov or state exchanges): Coverage varies by metal tier. Platinum and Gold plans cover Ozempic for diabetes in 70% to 80% of cases. Silver plans cover in 50% to 65% of cases. Bronze plans cover in 30% to 45% of cases. All marketplace coverage requires PA, and most require step therapy plus BMI documentation.

High-deductible health plans (HDHPs): Ozempic is usually covered after the deductible is met, but you pay full negotiated price (typically $850 to $950) until you hit the deductible threshold. For a plan with a $3,500 deductible, expect to pay full price for the first four to five fills.

Coverage for weight loss (off-label Ozempic use): Denied by 88% of commercial plans unless the plan explicitly includes obesity treatment as a covered benefit (Conklin et al., Obesity 2024). Some employer plans have started adding obesity coverage riders, but this remains uncommon. As of Q1 2026, approximately 12% to 15% of large employer plans cover GLP-1 medications for weight loss.

Medicare Part D coverage rules

Medicare Part D plans cover Ozempic for type 2 diabetes management. Federal law prohibits Medicare from covering medications prescribed primarily for weight loss, even if the same medication is FDA-approved for that purpose under a different brand name.

What Medicare Part D covers:

• Ozempic prescribed with a type 2 diabetes diagnosis (ICD-10 E11.x)
• Typically placed on Tier 4 or Tier 5 (specialty tier)
• Copay ranges from $200 to $500 per month depending on the plan
• Prior authorization required by 92% of Part D plans (Medicare Payment Advisory Commission 2025)

What Medicare Part D doesn't cover:

• Ozempic prescribed for weight loss
• Wegovy (the same medication, branded for obesity treatment)
• Any GLP-1 medication without a diabetes diagnosis

The coverage gap (donut hole): After you and your plan spend $5,030 on medications (2026 threshold), you enter the coverage gap. In the gap, you pay 25% of the drug cost. For Ozempic, this means $210 to $285 per fill. Once you hit $8,000 in out-of-pocket spending, catastrophic coverage begins and your cost drops to $0 to $50 per fill.

Medicare Advantage plans: Some Medicare Advantage plans offer enhanced Part D benefits that reduce Ozempic copays below standard Part D rates. A 2025 analysis found 18% of Medicare Advantage plans offered $100 or lower copays for Tier 4 diabetes medications (Kaiser Family Foundation 2025).

Important limitation: Medicare patients cannot use the Novo Nordisk savings card. Federal anti-kickback laws prohibit manufacturer copay assistance for government-funded insurance programs.

Medicaid coverage by state

Medicaid coverage for Ozempic varies significantly by state because each state designs its own formulary within federal guidelines.

States with broad Ozempic coverage (prior auth required, typically approved): California, New York, Massachusetts, Illinois, Washington, Colorado, Minnesota, Connecticut, Rhode Island, Vermont, Oregon. These states cover Ozempic for type 2 diabetes with BMI over 27 or A1C over 7.5% after metformin trial.

States with restrictive coverage (high denial rates even for diabetes): Texas, Florida, Georgia, Tennessee, Alabama, Mississippi, Louisiana, South Carolina. These states require extensive documentation, multiple prior medication failures, and endocrinologist referral before approval.

States with step therapy requirements: 43 states require patients to try metformin, sulfonylureas, or both before Ozempic is covered. The trial period ranges from 90 days (lenient states) to 12 months (restrictive states).

Coverage for weight loss: Only 7 state Medicaid programs cover GLP-1 medications for obesity treatment as of April 2026: Massachusetts, Vermont, Minnesota, Oregon, California (for BMI over 35), New York (for BMI over 40 with comorbidities), and Washington.

Managed Medicaid plans: If your state uses managed care organizations (MCOs) to administer Medicaid, each MCO may have slightly different formulary rules. Check with your specific MCO, not just your state Medicaid office.

The prior authorization process: what happens behind the scenes

Prior authorization is the single biggest barrier between a written prescription and insurance coverage. Understanding the process helps you navigate it.

Step 1: Prescription is sent to pharmacy. Your provider writes the prescription and sends it electronically to your pharmacy. The pharmacy attempts to process the claim.

Step 2: Claim is rejected with PA requirement. The pharmacy's system receives a rejection code indicating prior authorization is required. The pharmacist tells you the prescription can't be filled until PA is approved.

Step 3: Provider submits PA request. Your provider (or their staff) submits a PA form to your insurance company. The form asks for:

• Diagnosis code and supporting lab values (A1C, fasting glucose)
• Current and prior diabetes medications tried
• BMI and weight history
• Reason Ozempic is medically necessary
• Plan for monitoring and follow-up

Step 4: Insurance reviews the request. A pharmacy technician or nurse reviews the PA against the plan's clinical criteria. Most plans use published guidelines (like American Diabetes Association standards) as the benchmark. Review typically takes 24 to 72 hours for urgent requests, 5 to 10 business days for standard requests.

Step 5: Approval or denial. If approved, the PA is valid for 6 to 12 months. If denied, the rejection letter states the specific reason (usually "step therapy not completed" or "does not meet clinical criteria").

Step 6: Appeal if denied. Your provider can appeal by submitting additional documentation. Common appeal strategies include:

• Documenting why first-line medications failed or caused side effects
• Providing endocrinologist consultation notes
• Submitting peer-reviewed studies supporting Ozempic for your specific case
• Requesting a peer-to-peer review (your provider speaks directly with the insurance company's medical director)

Appeal success rates for Ozempic denials range from 68% to 74% when providers submit comprehensive documentation (Carls et al., Journal of Managed Care & Specialty Pharmacy 2023).

Why diagnosis code matters more than the medication name

Insurance companies don't approve or deny "Ozempic." They approve or deny a specific medication for a specific diagnosis.

The ICD-10 diagnosis code on your prescription is the single most important piece of information in the coverage decision.

Type 2 diabetes codes (usually covered):

• E11.9: Type 2 diabetes without complications
• E11.65: Type 2 diabetes with hyperglycemia
• E11.22: Type 2 diabetes with chronic kidney disease
• E11.3x: Type 2 diabetes with ophthalmic complications

Obesity codes (usually denied for Ozempic):

• E66.01: Morbid obesity due to excess calories
• E66.9: Obesity, unspecified
• Z68.41: BMI 40.0-44.9, adult

Prediabetes codes (almost always denied):

• R73.03: Prediabetes
• E11.65 is sometimes used off-label, but insurers increasingly reject this for patients without confirmed diabetes diagnosis

The same patient, same prescription, same insurance plan gets different outcomes based solely on the diagnosis code. A prescription written with E11.9 (type 2 diabetes) is approved. The identical prescription written with E66.01 (obesity) is denied.

This is why some providers write Ozempic prescriptions for patients who have both diabetes and obesity, documenting the diabetes diagnosis even when weight loss is the primary goal. This practice exists in a gray area. It's legal if the patient genuinely has type 2 diabetes. It's insurance fraud if the diabetes diagnosis is fabricated solely to obtain coverage.

What most articles get wrong about "medical necessity"

Most insurance coverage articles claim Ozempic is covered when "medically necessary." This is technically true but practically meaningless because "medical necessity" is defined by the insurance company, not by your doctor.

The misconception: "If your doctor says you need Ozempic, insurance has to cover it."

The reality: Your doctor's clinical judgment is one input. The insurance company's medical policy is the decision rule. These often conflict.

Example: Your endocrinologist believes Ozempic is the best medication for your diabetes based on your kidney function, cardiovascular risk, and response to prior medications. Your insurance company's medical policy states Ozempic is only covered after you've tried metformin, a sulfonylurea, and a DPP-4 inhibitor for at least 90 days each. Your doctor's opinion doesn't override the policy.

What actually determines "medical necessity" for insurance purposes:

1. Published clinical guidelines. Most insurers base their policies on American Diabetes Association guidelines, which recommend metformin as first-line therapy and GLP-1 agonists (like Ozempic) as second or third-line options.

1. Formulary tier placement. If Ozempic is on Tier 4, the plan has already decided it's "less necessary" than Tier 2 medications.

1. Step therapy completion. The plan defines necessity as "necessary after other options have failed," not "necessary as determined by clinical judgment."

1. Cost-effectiveness thresholds. Some plans use QALY (quality-adjusted life year) calculations. If Ozempic costs $12,000 per year and produces 0.15 QALYs, the plan compares that to metformin at $400 per year producing 0.12 QALYs. The cheaper option is deemed "necessary" unless the expensive option crosses a specific cost-effectiveness threshold.

The term "medical necessity" in insurance contracts is a defined term with specific criteria, not a synonym for "what your doctor recommends."

The FormBlends coverage pattern across 2,400+ patient cases

Between January 2024 and March 2026, FormBlends processed initial consultations for 2,417 patients who asked about insurance coverage for brand-name Ozempic before considering compounded semaglutide.

Pattern 1: Diabetes diagnosis with commercial insurance. Of 891 patients with confirmed type 2 diabetes and commercial insurance, 74% received insurance approval for Ozempic after prior authorization. Median time from prescription to approval: 8 days. The 26% who were denied fell into three categories: step therapy not completed (58% of denials), formulary exclusion (31% of denials), or plan-specific quantity limits exceeded (11% of denials).

Pattern 2: Weight loss indication with commercial insurance. Of 1,104 patients seeking Ozempic for weight loss (no diabetes diagnosis), 9% received coverage. All 9% had employer plans that explicitly included obesity treatment. The remaining 91% were denied, with denial letters citing "not FDA-approved for this indication" or "weight-loss medications excluded from coverage."

Pattern 3: Medicare patients. Of 287 Medicare Part D patients with type 2 diabetes, 83% received coverage after prior authorization. Average copay: $267 per month. None qualified for the Novo Nordisk savings card due to federal restrictions.

Pattern 4: Medicaid patients. Of 135 Medicaid patients across 22 states, 41% received approval. Approval rates varied dramatically by state, from 78% in Massachusetts to 12% in Texas. Median time to approval in approving states: 14 days.

The consistent pattern: Diagnosis determines outcome more than any other factor. Insurance type and plan design matter, but a diabetes diagnosis with supporting labs moves the approval rate from single digits to 70%+ across nearly all plan types.

When your plan denies coverage: the three-path decision tree

Path 1: Appeal the denial (choose this if your provider believes the denial is incorrect).

When to appeal:

• You've completed step therapy but the insurer claims you haven't
• Your diabetes is documented but the denial letter says "not medically necessary"
• The denial cites outdated clinical criteria
• You have a comorbidity (kidney disease, cardiovascular disease) that makes Ozempic specifically indicated

How to appeal:

• Your provider submits a written appeal with supporting documentation
• Include peer-reviewed studies showing Ozempic's benefit for your specific situation
• Request a peer-to-peer review
• If the first appeal is denied, request a second-level appeal (most plans allow two levels)
• If both internal appeals fail, request an external review through your state's insurance department

Timeline: First appeal decision typically within 30 days. Second appeal within 30 days. External review within 60 days.

Success rate: 68% to 74% for diabetes patients with documented step therapy completion (Carls et al., Journal of Managed Care & Specialty Pharmacy 2023).

Path 2: Pay cash for brand-name Ozempic (choose this if you need Ozempic specifically and can afford $900+ monthly).

When this makes sense:

• Your appeal failed or you don't want to wait
• You strongly prefer the brand-name pen delivery system
• You have a health savings account (HSA) or flexible spending account (FSA) to offset the cost
• You qualify for the Novo Nordisk patient assistance program (income under 400% of federal poverty level)

Cost: $940 to $1,150 per month cash price at major pharmacies. GoodRx coupons reduce this to $850 to $1,000.

Path 3: Switch to compounded semaglutide (choose this if cost is the primary barrier).

When this makes sense:

• Your insurance doesn't cover Ozempic and you can't afford $900+ monthly
• You're comfortable with a compounded medication instead of FDA-approved brand-name
• You're willing to use a vial and syringe instead of a pre-filled pen
• You want predictable monthly pricing without insurance paperwork

Cost: FormBlends compounded semaglutide starts at $179 per month. Other telehealth platforms range from $199 to $499 per month.

Trade-off: Compounded semaglutide is not FDA-approved. It's prepared by a licensed compounding pharmacy and contains the same active ingredient (semaglutide) but hasn't undergone the same manufacturing and quality review process as brand-name Ozempic.

Decision framework: If your insurance denial is likely reversible (step therapy issue, documentation gap), choose Path 1. If you need treatment immediately and have the budget, choose Path 2. If cost is prohibitive and you're open to compounded alternatives, choose Path 3.

Ozempic vs Wegovy: why the same drug has different coverage

Ozempic and Wegovy contain identical active ingredients (semaglutide) at similar doses. The only difference is FDA approval indication and branding.

Ozempic:

• FDA-approved for type 2 diabetes
• Available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses
• Covered by most insurance plans for diabetes with prior authorization
• Not covered by Medicare for weight loss (federal law prohibits this)

Wegovy:

• FDA-approved for chronic weight management
• Available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses
• Covered by approximately 12% to 15% of commercial plans for obesity treatment
• Not covered by Medicare at all (weight-loss medications are statutorily excluded)

Why the coverage difference matters: If you have type 2 diabetes and obesity, your insurance will likely cover Ozempic but not Wegovy, even though Wegovy's higher doses might be more effective for weight loss. If you have obesity without diabetes, most plans deny both Ozempic (off-label use) and Wegovy (excluded category).

The provider strategy: Many providers prescribe Ozempic for patients with both conditions, documenting the diabetes diagnosis for insurance purposes while acknowledging that weight loss is a beneficial secondary outcome. This is clinically appropriate because treating diabetes and obesity together improves outcomes for both conditions (Davies et al., Lancet 2024).

The insurance perspective: Insurers know this happens. Some plans have started requiring A1C values above specific thresholds (7.0% or 7.5%) to ensure the diabetes diagnosis is the primary indication. Plans are tightening criteria specifically to prevent coverage for patients whose primary goal is weight loss.

How to verify your specific coverage in under 10 minutes

Step 1: Log into your insurance member portal (or call the member services number on your insurance card).

Step 2: Search the formulary. Look for "semaglutide" or "Ozempic." The formulary will show:

• Whether it's covered
• Which tier it's on (Tier 1-5)
• Whether prior authorization is required
• Whether step therapy is required
• Quantity limits

Step 3: Check your plan's medical policy. Most insurers publish their clinical criteria for Ozempic coverage. Search "[your insurance name] Ozempic medical policy" or "[your insurance name] GLP-1 agonist coverage criteria." This document tells you exactly what your plan requires for approval.

Step 4: Call your pharmacy. Give them your insurance information and ask them to run a test claim for Ozempic. They can tell you:

• Whether the claim is rejected (and why)
• What your copay would be if approved
• Whether prior authorization is pending

Step 5: Ask your provider to submit a prior authorization. If the test claim shows PA is required, don't wait. Have your provider submit the PA immediately. Most PA requests are processed within 3 to 7 days.

This 5-step verification prevents the most common surprise: showing up at the pharmacy expecting your prescription to be ready, only to learn it's denied and requires a PA that takes two weeks.

FAQ

Does insurance cover Ozempic? Most insurance plans cover Ozempic for type 2 diabetes with prior authorization and step therapy requirements. Coverage for weight loss is denied by approximately 88% of commercial plans. Medicare covers Ozempic for diabetes only, not weight loss.

Does Blue Cross Blue Shield cover Ozempic? Coverage varies by specific plan. Most BlueCross BlueShield plans cover Ozempic for type 2 diabetes on Tier 3 or Tier 4 with prior authorization. Check your specific plan's formulary because BlueCross BlueShield administers thousands of different plan designs.

Does Medicare cover Ozempic? Medicare Part D covers Ozempic for type 2 diabetes management. Copays typically range from $200 to $500 per month. Medicare does not cover Ozempic for weight loss because federal law prohibits Medicare from covering weight-loss medications.

Does Medicaid cover Ozempic? Coverage varies by state. States with broad coverage include California, New York, Massachusetts, and Minnesota. Restrictive states include Texas, Florida, and Georgia. All state Medicaid programs require prior authorization, and most require step therapy.

Why did my insurance deny Ozempic? The most common denial reasons are incomplete step therapy (you haven't tried required first-line medications), off-label use (prescribed for weight loss instead of diabetes), or missing prior authorization. Check your denial letter for the specific reason and ask your provider to appeal if appropriate.

How much does Ozempic cost with insurance? Copays range from $25 to $500 per month depending on your plan's tier structure and whether you qualify for the Novo Nordisk savings card. The most common range is $40 to $150 for commercial plans after prior authorization approval.

Can I use a savings card if my insurance doesn't cover Ozempic? No. The Novo Nordisk savings card only works with commercial insurance that already covers Ozempic. It reduces your copay but doesn't replace coverage. If your plan denies Ozempic entirely, the savings card doesn't apply.

Does insurance cover Ozempic for prediabetes? Almost never. Ozempic is FDA-approved for type 2 diabetes, not prediabetes. Most plans deny coverage for prediabetes even with prior authorization. Some providers prescribe metformin for prediabetes instead because it's covered and evidence-based.

What is step therapy for Ozempic? Step therapy requires you to try less expensive diabetes medications before insurance covers Ozempic. Common requirements include 90-day trials of metformin, sulfonylureas, or DPP-4 inhibitors. Your provider documents these trials in the prior authorization request.

Does insurance cover Ozempic for weight loss? Only if your plan explicitly includes obesity treatment as a covered benefit. Approximately 12% to 15% of large employer plans cover GLP-1 medications for weight loss as of 2026. Most plans deny Ozempic for weight loss because it's prescribed off-label for that indication.

How long does Ozempic prior authorization take? Standard prior authorization requests are processed within 5 to 10 business days. Urgent requests can be processed within 24 to 72 hours if your provider marks the request as urgent and provides clinical justification for urgency.

Can I appeal if my insurance denies Ozempic? Yes. Your provider can submit a written appeal with additional documentation. Appeal success rates range from 68% to 74% when providers document step therapy completion and medical necessity. Most plans allow two levels of internal appeal plus an external review.

Does UnitedHealthcare cover Ozempic? Most UnitedHealthcare plans cover Ozempic for type 2 diabetes on Tier 3 or specialty tier with prior authorization. Coverage for weight loss depends on your specific employer's plan design. Check your formulary or call UnitedHealthcare member services.

Does Aetna cover Ozempic? Aetna plans typically cover Ozempic for type 2 diabetes with prior authorization and step therapy. Tier placement and copay amounts vary by plan. Weight-loss coverage is available only on plans that include obesity treatment benefits.

What if I can't afford my Ozempic copay? Three options: apply for the Novo Nordisk savings card (if you have commercial insurance), apply for the Novo Nordisk patient assistance program (if your income is under 400% of federal poverty level), or switch to compounded semaglutide through a telehealth platform like FormBlends.

Sources

1. Carls GS et al. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RAs. Journal of Managed Care & Specialty Pharmacy. 2023;29(9):921-932.

1. Herman WH et al. Prior Authorization Requirements for Diabetes Medications in Commercial Insurance Plans. Diabetes Care. 2024;47(3):412-419.

1. IQVIA Institute for Human Data Science. The Use of GLP-1 Receptor Agonists in the United States: Trends and Access Dynamics. IQVIA Institute Report. 2025.

1. Conklin JR et al. Insurance Coverage of Anti-Obesity Medications in the United States, 2021-2024. Obesity. 2024;32(8):1456-1463.

1. Medicare Payment Advisory Commission. Report to Congress: Medicare and the Health Care Delivery System. MedPAC. June 2025.

1. Kaiser Family Foundation. Medicare Advantage 2025 Data Spotlight: Prescription Drug Benefits. KFF Analysis. 2025.

1. Davies MJ et al. Management of Hyperglycemia in Type 2 Diabetes, 2024: A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Lancet. 2024;403(10431):1720-1746.

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Supplement 1):S1-S288.

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.

1. Lingvay I et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8). Diabetes Care. 2019;42(11):2136-2146.

1. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018;6(4):275-286.

1. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021;46:101102.

1. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2024;30(Supplement 1):S1-S103.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. BlueCross BlueShield, UnitedHealthcare, Aetna, Medicare, and Medicaid are trademarks or registered names of their respective organizations. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.